ライフサイエンスコーパス: syringe

1 vice, although not when injected by a needle-syringe.

2 ite reactions than was the use of needle and syringe.

3 of water for the calibration of the sampling syringe.

4 e-free jet injector compared with needle and syringe.

5 injection of antigen using a 27G needle and syringe.

6 e to influenza vaccine given with needle and syringe.

7 armaJet, Golden, CO, USA) or with needle and syringe.

8 water extraction using a modified disposable syringe.

9 nge pumps, requiring only a single hand-held syringe.

10 easily controlled by the operator through a syringe.

11 ds (HA), then combined via a double-barreled syringe.

12 any respects, resembles and functions like a syringe.

13 tic filter holders connected to a disposable syringe.

14 k adapter connected to a HTC PAL autosampler syringe.

15 er seven extraction cycles of air pumping by syringe.

16 f a reaction-diffusion front within a 50 muL syringe.

17 robes cultured from patients and from unused syringes.

18 ntravitreal bevacizumab preloaded in insulin syringes.

19 s, their location, and whether they sell OTC syringes.

20 g a single vial of bevacizumab into multiple syringes.

21 the majority of patients and from all unused syringes.

22 Pharmacists prepared the syringes.

23 densities of IDUs had limited access to OTC syringes.

24 void volume (32 microL) for 1-mL tuberculin syringes.

25 to prolonged virus survival in contaminated syringes.

26 to sharing of injection equipment other than syringes.

27 njected in vivo through conventional needled syringes.

28 with a combination of patency and reflux on syringing.

29 ing and minimal or no reflux on nasolacrimal syringing.

30 mptoms of watering and 50% to 100% reflux on syringing.

31 ith 306 doses of mRNA (80-640 mug) by needle-syringe (18 intradermally and 24 intramuscularly) or nee

32 elatively high prevalence of sharing needles/syringes (18%-28% in the last injection), the low levels

33 Using a second sterile syringe, 20 ml of blood was obtained and inoculated in 1

34 icone oil droplets compared with priming the syringe (6.4% [47 of 739] vs 0.5% [12 of 2627]; Fisher e

35 oral interventions, substance-use treatment, syringe access, syringe disinfection, and multicomponent

36 elded viable virus from 96%, 71%, and 52% of syringes after storage at 4 degrees, 22 degrees, and 37

37 ssed trends in nationwide introduction of AD syringes against measles catch-up SIAs and GAVI funding

38 microscopy apparatus, and a set of motorized syringes, all controlled by a computer.

39 r persons who inject drugs (PWIDs) stockpile syringes, an important and novel aspect of NSP coverage.

40 -automated magnetic stirring-assisted lab-in-syringe analytical procedure has been developed for the

41 d glutamic acid, forms a solid-like gel in a syringe and can be shear-thin delivered to the lumen of

42 Higher rates of syringe and equipment sharing and lower prevalence of op

43 evice was compared to delivery by needle and syringe and evaluated for safety and immunogenicity.

44 n any microscope and operated using only one syringe and one external valve, making it accessible to

45 clinics, prison health services, and needle syringe and oral substitution therapy programs; improvin

46 bly (shear-thinning) when injected through a syringe and then reassemble within seconds (self-healing

47 in mice that were inoculated with needle and syringe and was found to be equivalent to that of wild-t

48 l as HIV-1 infectivity could be abrogated in syringes and filters.

49 low void volume (2 microL) for 1-mL insulin syringes and high void volume (32 microL) for 1-mL tuber

50 In 2000, reuse of disposable syringes and inadequately sterilized syringes resulted i

51 acizumab and placebo were drawn into plastic syringes and incubated at -20 degrees C, 4 degrees C, an

52 xty-six musculoskeletal procedures involving syringes and needles were randomized to either an RPD gr

53 of injection safety equipment, including AD syringes and safety boxes, training, and procurement of

54 t was anatomic patency based on nasolacrimal syringing and categorized as (a) fully patent, minimal,

55 patent canalicular system as demonstrated by syringing and probing.

56 fixed-volume capillary, a pre-filled tube, a syringe, and a dropper); this kit would cost $0.50 whe

57 -healing behavior, can be injected through a syringe, and rapidly recover their mechanical properties

58 ne oil used for the lubrication of prefilled syringes, and it is difficult to differentiate microdrop

59 d from 36.8% to 26.0% (P = .007) for sharing syringes, and the proportion of undiagnosed HIV infectio

60 t of rapid, simple, 1-step, room-temperature syringe-and-vial radiolabeling of (68)Ga radiopharmaceut

61 Although pharmacy sales of OTC syringes are associated with reduced injection-mediated

62 ssure regulator, assembly of stainless-steel syringes, assembly of a continuous flow system with mult

63 igned to receive vaccinations via needle and syringe at 0 and 8 weeks, 0 and 12 weeks, 0, 4, and 8 we

64 ula, ratio of synovial enhancement to saline syringe at full dose = 0.337 + 1.070 x ratio of synovial

65 70 x ratio of synovial enhancement to saline syringe at half dose, can be used to convert the normali

66 We have developed a suite of whole-blood, syringe-based assay systems that can be used to reproduc

67 he logistic obstacles surrounding needle-and-syringe-based immunization as well as to facilitate the

68 transferred to the GC x GC instrument via a syringe-based interface mounted on an autosampler.

69 onally, as silicone oil-lubricated prefilled syringes become a favored primary packaging for biothera

70 Priming the syringe before injection was associated with a lower fre

71 From May to November 2016, nonpriming the syringe before the intravitreal injection had a higher r

72 of Standards and Technology (NIST) with mock syringe blanks used in the construction of a commerciall

73 on (AOR=3.05; 95% CI 1.40, 6.66), and recent syringe borrowing (AOR 1.59; 95% CI 1.07, 2.36).

74 version, prevalent HIV infection, and recent syringe borrowing.

75 All 39 countries stopped using sterilizable syringes by 2004.

76 avitreal bevacizumab was prepared in insulin syringes by a compounding pharmacy.

77 se extraction (D-mu-SPE) based on the lab-in-syringe concept is reported.

78 es that using hematophagous flies as 'flying syringes' constitutes an interesting approach to investi

79 occurring during shipping was mimicked with syringes containing bevacizumab.

80 domized to receive injections from identical syringes containing placebo or anakinra subcutaneously o

81 e compounding procedures used to prepare the syringes containing the bevacizumab.

82 Bevacizumab repackaged in plastic syringes could contain protein aggregates and is contami

83 rticipants reported higher rates of adequate syringe coverage, linkage to HIV care and OST.

84 way, total injections in the last month, and syringes currently stockpiled in 2014.

85 gnment is achieved by the shearing forces of syringe delivery, it is also dependent on the amino acid

86 ns, substance-use treatment, syringe access, syringe disinfection, and multicomponent interventions.

87 A sensitive and selective automated in-syringe dispersive liquid-liquid microextraction (DLLME)

88 gh coverage of both NSP and OST (>200 needle-syringes distributed per PWID and >40 OST recipients per

89 low according to WHO indicators (<100 needle-syringes distributed per PWID per year; <20 OST recipien

90 33 (uncertainty interval [UI] 21-50) needle-syringes distributed via NSP per PWID annually, and 16 (

91 e programmes is cost-effective compared with syringe distribution alone, but when combined with linka

92 cessation and "breaks"; (5) scaled-up needle/syringe distribution, HCV treatment, and vaccines, accor

93 -contamination included reuse of needles and syringes during dilutions and use of common flow hoods f

94 during follow-up, and having shared needles/syringes during follow-up, HCV incidences per 100 person

95 emical experiment, the electrode within this syringe-electrode assembly can be introduced into the in

96 We found that syringe electrodes are more effective than the conventio

97 for NIST to calibrate these epoxy-based mock syringes enabled, for the first time to our knowledge, t

98 ffective interventions, including needle and syringe exchange programmes, opioid substitution therapy

99 tion services should be provided (needle and syringe exchange programs, supervised injection, and ava

100 Insulin syringes failed to yield viable HCV beyond day 1 at all

101 raction efficacy were investigated including syringe fill strokes, syringe pull up volume, pull up de

102 A syringe filled with diluted iodine contrast material was

103 A 30-mL syringe filled with skim milk was inserted into a syring

104 mples, based on the capture of bacteria on a syringe filter, and the infection of targeted bacterial

105 ively coupled plasma mass spectrometry after syringe filtration (0.45 mum polyethersulfone membrane).

106 ge needle on a 3-way T-extension into a 3-mL syringe, followed by immediate infusion of absolute alco

107 All countries continued with AD syringes for immunization after measles catch-up SIAs an

108 itional Bacillus Calmette-Guerin needles and syringes for the administration of fIPV.

109 roof-of-concept of a novel integrated lab-in-syringe/gas-liquid separation (LIS/GLS) batch-flow syste

110 ties independently measured (90)Y in a 10-mL syringe geometry with 30 dose calibrator models from 3 d

111 ed as non-inferior to that of the needle and syringe group if both the upper bound of each of the thr

112 jet injector group and 574 in the needle and syringe group).

113 zed to either an RPD group or a conventional syringe group, and pain, quality, safety, and physician

114 litates the concurrent operation of multiple syringes have been designed, enabling the simultaneous d

115 de an alternative to conventional needle-and-syringe immunisation, and potentially offer improved imm

116 lonal antibody solutions stored in prefilled syringes in stressed stability studies.

117 to determine whether inclusion of stockpiled syringes in the measure improved sensitivity in discrimi

118 21 countries that had already introduced AD syringes in their national program.

119 otential applications of the electrochemical syringe include fluid dispensing in nanolithography and

120 A programmable dual-syringe infusion pump is used to introduce a solution of

121 Here we report novel syringe-injectable bioadhesive hydrogels with inherent a

122 We demonstrate several applications of syringe-injectable electronics as a general approach for

123 overcome this challenge by demonstrating the syringe injection (and subsequent unfolding) of sub-micr

124 Moreover, syringe injection enables the delivery of flexible elect

125 0, 4, and 8 weeks via single-dose needle and syringe injection in one deltoid or split-dose needle an

126 trategy for delivery via conventional needle-syringe injection of large preformed macroporous scaffol

127 hip access ports to a fluids cartridge and a syringe injection port and provides sample introduction

128 electronics implanted into rodent brains by syringe injection that exhibit promising chronic tissue

129 versely, intradermal or intramuscular needle-syringe injection was ineffective, with only one partici

130 by using a split-bolus protocol with a dual-syringe injector and an initial bolus of contrast medium

131 contrast-medium-only protocol with a single-syringe injector; 25 were injected by using a biphasic p

132 ted by using a biphasic protocol with a dual-syringe injector; and 25 were injected by using a split-

133 f whether mice were infected artificially by syringe inoculation or naturally by tick bite.

134 y when subsequently administered to mice via syringe inoculation.

135 elivered by means of a hypodermic needle and syringe into muscle, in a process that bypasses the epid

136 A syringe is then used to actively transport the analyte a

137 mal dose by needle and syringe or disposable-syringe jet injector at a second visit.

138 s of IPV by needle and syringe or disposable-syringe jet injector compromises the immunity generated,

139 dose using needle and syringe or disposable-syringe jet injector.

140 ncluding intradermal adapters and disposable-syringe jet injectors, have also been developed and eval

141 Many Gram-negative bacterial pathogens use a syringe-like apparatus called a type III secretion syste

142 f seven stacked MCE rings, and PqiB adopts a syringe-like architecture.

143 These include syringe-like injection (bacteria and nematodes), common

144 The bacteria use a syringe-like macromolecular assembly to secrete various

145 bacteria into epithelial cell cytosol via a syringe-like organelle known as the type III secretion s

146 ium enteropathogenic Escherichia coli uses a syringe-like type III secretion system (T3SS) to inject

147 Pathogenic Gram-negative bacteria use syringe-like type III secretion systems (T3SS) to inject

148 rtantly, AuNPs-embedded paper-based lab-in-a-syringe (LIS) device is developed as a sensing strategy.

149 The flow-based analyzer features a lab-in-syringe (LIS) setup with an integrated stirring system,

150 et collagenase labeling between perfused and syringe-loaded pancreases.

151 ore and after collagenase infusion by manual syringe-loading (n=10) or recirculating perfusion (n=8),

152 till collected using the 150-year-old needle/syringe method.

153 0, 4, 8) by Biojector(R) 2000 or needle and syringe (N/S) and boosted IM at week 24 with VRC-HIVADV0

154 edle-free jet injector (n=627) or needle and syringe (n=623).

155 lesh (ca. 10mg) was sampled directly using a syringe needle and placed in a glass insert for liquid e

156 cient cells by passage through a narrow-bore syringe needle and purifying the intact chloroplasts by

157 A novel syringe needle-based sampling approach coupled with liqu

158 damage during ejection through a fine-gauge syringe needle.

159 ilm metallic glass (TFMG) for the coating of syringe needles and compares the results with those obta

160 separated from the aqueous phase within the syringe of an automated syringe pump.

161 The magnetic bar was placed inside the syringe of an automatic bidirectional syringe pump, enab

162 d 26.0 (0) mL for grade 4 FLA (1 mL equals 1 syringe of HA filler).

163 a towel (wipe group) or suction with a bulb syringe of the mouth and nostrils (suction group).

164 Seven unused syringes of bevacizumab prepared by the compounding phar

165 d a combination of interconnected valves and syringes operated by computer controlled pumps and ensur

166 or fractional intradermal dose by needle and syringe or disposable-syringe jet injector at a second v

167 ional intradermal doses of IPV by needle and syringe or disposable-syringe jet injector compromises t

168 s a full or fractional dose using needle and syringe or disposable-syringe jet injector.

169 tion in one deltoid or split-dose needle and syringe or needle-free injection with the Stratis device

170 1 intradermally or intramuscularly by needle-syringe or one of three needle-free devices.

171 and aseptic technique (for example, reuse of syringes or lancing devices).

172 e RPD and 4.83 +/- 3.22 for the conventional syringe; P < 0.001) and a 49.5% reduction (95% CI 34-64%

173 uroxime may be administered using pre-filled syringes (PFS), either prepared in hospital by reconstit

174 ion consumables such as Vacutainer stoppers, syringe plungers, and sample vial septa.

175 se of this outbreak was contamination during syringe preparation by the compounding pharmacy.

176 halmitis after intravitreal bevacizumab from syringes prepared by a single compounding pharmacy.

177 is/oralis in vitreous specimens and 7 unused syringes prepared by the compounding pharmacy at the sam

178 bial contamination of bevacizumab-containing syringes prepared from the same vial of drug can be avoi

179 consisted of a transducer with a needleless syringe pressed over each flank.

180 Drug Reporting System study, PWIDs reported syringes procured and given away, total injections in th

181 ctice, allowing PWIDs greater flexibility in syringe procurement practices, promoting greater NSP cov

182 Needle and syringe program (NSP) coverage is commonly used to asses

183 CI: 0.06-0.67), and frequent users of needle/syringe program services had lower HIV incidence (0% in

184 e to evaluate the association between needle/syringe program use and HIV incidence.

185 one homelessness service, and one needle and syringe programme).

186 on interventions for PWID include needle and syringe programmes (NSP), opioid substitution therapy (O

187 prenorphine in five countries and needle and syringe programmes in three countries), with none of the

188 st therapies and does not support needle and syringe programmes-with neither available in prisons-des

189 n therapy (OST) and high-coverage needle and syringe programs (HCNSP) cannot substantially reduce hep

190 cy: opioid agonist therapy (OAT), needle and syringe programs (NSPs), HIV testing and treatment (Test

191 therapy and increased coverage of needle and syringe programs in North America.

192 investigated including syringe fill strokes, syringe pull up volume, pull up delay and volume in the

193 ct formation is suppressed even without slow syringe pump addition of the ethyl diazoacetate.

194 ble to any research laboratory, using only a syringe pump and a conventional thermocycler.

195 ection of cells, using disposable devices, a syringe pump and a low-cost power supply that provides a

196 lus injector) was placed in-line between the syringe pump and microdialysis probe.

197 Perfusion medium was infused by a syringe pump at a constant infusion rate of 5 muL/min.

198 s infused as a postcolumn addition using the syringe pump at the time of elution of the analyte.

199 A single syringe pump delivers sample/reagents to the chip for nu

200 allel access through the use of a vacuum and syringe pump for delivery of immobilization buffer (IB)

201 latter strategy permits the use of a robust syringe pump for the purpose.

202 Under the optimal conditions (including syringe pump high dilution), the macrolactones were prod

203 One syringe pump infused a carrier.

204 With syringe pump injection, the detector is evaluated by mea

205 The syringe pump inside the TDS was devised in such a way th

206 lected sample is periodically aspirated by a syringe pump into a holding loop and then delivered to a

207 A syringe pump is used to systematically investigate the e

208 ought to have occurred by contamination of a syringe pump outside the laminar-flow curtain of a patie

209 ls, 3 mm wide by 1.5 mm deep, connected to a syringe pump through standard, threaded fittings.

210 luidics system can be operated with a single syringe pump to introduce drug compounds (which takes ap

211 The setup was operated with a syringe pump, delivering reagents to the surface through

212 de the syringe of an automatic bidirectional syringe pump, enabling dispersion and subsequent magneti

213 The device only needs a syringe pump, thus removing the use of complex, expensiv

214 nd insulin were continuously administered by syringe pump.

215 ous phase within the syringe of an automated syringe pump.

216 troduced for extended periods of time with a syringe pump.

217 vely) templation method without the use of a syringe pump.

218 ge filled with skim milk was inserted into a syringe pump.

219 m manually using a Teflon tube attached to a syringe pump; this method is simple enough it should be

220 egrees C in 24 h without photoirradiation or syringe-pump addition.

221 re specialized engineering equipment such as syringe pumps and long time frames (hours) to develop a

222 using gravity-driven flow in the absence of syringe pumps and portable fluorescence imaging solution

223 (2-3 d), and they can be operated using two syringe pumps for lysed blood samples (7.5 ml in 12.5 mi

224 The instrument uses two syringe pumps to handle three liquids.

225 ntrol within the device removes the need for syringe pumps, requiring only a single hand-held syringe

226 n miniature off-the-shelf components such as syringe pumps, valves, and pressure controllers which co

227 a continuous flow system from reactor coils, syringes, pumps, in-line liquid-liquid separators, dryin

228 e is known about the factors associated with syringe purchase among injection drug users (IDUs).

229 ral, and spatial factors associated with OTC syringe purchase by IDUs.

230 Notably, the prevalence of OTC syringe purchase was 53% lower among African-American ID

231 upply were independently associated with OTC syringe purchases.

232 tor enhancing resistance against Pseudomonas syringe pv tomato DC3000.

233 aureus, and, for the first time, Pseudomonas syringe pv. actinidiae.

234 y against the bacterial pathogen Pseudomonas syringe pv. tomato (Pst) DC3000 in the salicylic acid (S

235 in laboratories using widely available three-syringe quench flow mixers and inexpensive reagents to s

236 posable syringes and inadequately sterilized syringes resulted in 39% of all injections being unsafe,

237 d to shared saline bags contaminated through syringe reuse.

238 e membraneless GLS located at the top of the syringe's valve in the upright position.

239 alifornia law allowed over-the-counter (OTC) syringe sales pending local authorization.

240 essential oil, avoiding difficulties in the syringe sample withdrawal process, prior to GC injection

241 f a logging system, which is equipped with a syringe sampler and sensors for the measurement of stand

242 The syringe samples drawn during continuous profiling were u

243 A-ICOS isotopic N2O laser analyzer through a syringe septum port.

244 rophylaxis (PrEP) for HIV prevention through syringe service programmes has the potential to save liv

245 NTERPRETATION: Naloxone distribution through syringe service programmes is cost-effective compared wi

246 rgency was declared on March 26, 2015, and a syringe-service program in Indiana was established for t

247 ith hepatitis C virus lived >10 miles from a syringe services program.

248 This syringe-shaped 3.5-MDa macromolecular assembly spans bot

249 HIV prevention and treatment indicators were syringe sharing (n=35) and prevalence of HIV infection a

250 A linear decrease in syringe sharing behavior was observed over time after HC

251 6; 95% confidence interval, 1.03-23.92), but syringe sharing was not (adjusted HR, 0.91).

252 me have questioned whether underreporting of syringe sharing, a stigmatized behavior, has led to misa

253 re not attributable to underascertainment of syringe sharing.

254 a, or was named by another case patient as a syringe-sharing or sexual partner.

255 The number of times a contact was named as a syringe-sharing partner by a case patient was significan

256 UNICEF AD syringe shipments to sub-Saharan Africa increased from 1

257 Pressure-driven FNGs added to a syringe show potential to harvest energy in blood vessel

258 esults allow the (68)Ge activity of the mock syringe source to be expressed in terms of equivalent (1

259 esponse ratios for a (68)Ge solid epoxy mock syringe source used in activity calibrators as a long-li

260 y enabled NIST to calibrate epoxy-based mock syringe sources with a relative combined standard uncert

261 published methodology, solution-filled mock syringe sources, identical in geometry to the solid (68)

262 standards, while (13)C-BDE-100 was used as a syringe standard.

263 Three-quarters of the sample reported syringe stockpiling, and stockpiling was positively asso

264 the type of drug injected, and the source of syringe supply were independently associated with OTC sy

265 -3.7%, allowing users of the commercial mock syringe surrogate source to calibrate their activity cal

266 apparatus (TTSA) is the molecular needle and syringe that form the energized conduit between the bact

267 on might offer an alternative to needles and syringes that avoids the issue of needle phobia and the

268 leaves by one of three methods: a needleless syringe, the agrodrench method or by pricking with a too

269 gative pathogens, comprises a trans-envelope syringe, the injectisome, with a cytoplasm-facing transl

270 ion of absolute alcohol from a separate 1-mL syringe through the other arm of the T-extension.

271 deformation, and could be injected through a syringe to adhere to the convex contour of a tissue surf

272 the type III secretion system as a molecular syringe to inject type III secreted effector (T3SE) prot

273 retion system which functions as a molecular syringe to translocate bacterial effector proteins direc

274 sterilizable syringes with auto-disable (AD) syringes to improve injection safety in 39 African count

275 Reuse of syringes to redose patients, with resulting contaminatio

276 y due to the resilience of the virus and the syringe type.

277 saline bags were probably contaminated when syringes used to draw blood from venous catheters were r

278 g assisted DLLME were carried out inside the syringe void volume as a size-adaptable yet sealed mixin

279 re obtained for a sample volume equal to the syringe volume (5 mL).

280 A 25 gauge needle with 1 mL mounted syringe was filled with the tissue culture medium.

281 iated with bevacizumab prepared with insulin syringes was documented.

282 o the pharmacy that prepared the bevacizumab syringes was summarized.

283 In the pilot study, left-over blood gas syringes were collected for further laboratory analysis.

284 Prefilled syringes were dispensed with the group allocation concea

285 Syringes were loaded with blood spiked with HCV reporter

286 Syringes were stored at 4 degrees C, 22 degrees C, and 3

287 ral NIST-constructed epoxy-based (68)Ge mock syringes were then used as artifact standards to determi

288 d to the delivered volume from the injection syringe, which required a correction factor of 0.973, at

289 njections were administered via conventional syringe with a 27-gauge needle.

290 d by injecting the samples into them using a syringe with a needle or a pipet tip, and then sealing t

291 it was demonstrated that by flushing the EME-syringe with acidic wash buffer and reverting the applie

292 lows gel/cell constructs to be delivered via syringe with precision to target sites.

293 d bevacizumab was delivered using 300 microL syringes with 5/16-inch, 30-gauge fixed needles.

294 b, 1.25 mg/0.05 mL, was delivered in insulin syringes with a 31-gauge needle.

295 ing in replacing disposable and sterilizable syringes with auto-disable (AD) syringes to improve inje

296 Intravenous (i.v.) tubing connected the syringe within the pump to a glass capillary tube (inter

297 owever, 58.7% of recent initiates had shared syringes within the past 30 days compared with 33.6% dur

298 Increased access to OTC syringes would potentially prevent blood-borne infectiou

299 Tuberculin syringes yielded viable virus from 96%, 71%, and 52% of

300 mperatures except 4 degrees , in which 5% of syringes yielded viable virus on day 7.